Physicians' Academy for Cardiovascular Education

LDL-c & PCSK9i in Clinical Cardiology

European experts discuss the importance of targeting LDL-c in patients at increased CV risk and the potential role of PCSK9 inhibition - More videos to be added

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh

Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

3' education - Mar. 19, 2019 - Anne Carol Goldberg, MD

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach

What is the science and outcome supporting lower LDL-c targets?

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana

LDL-c as target in cardiology: The road towards lower targets

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France - Online CME

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK

Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL. USA - Prof. Wouter Jukema - LUMC, The Netherlands

Low LDL-c and TG levels associated with risk of hemorrhagic stroke in women

Literature - Apr. 18, 2019 - Rist PM et al., - Neurology 2019

In a large, prospective cohort of women, those with LDL-c <70 mg/dL and potentially those with LDL-c ≥160 mg/dL and those with low TG, showed a higher risk of hemorrhagic stroke.

Majority of statin-eligible US adults not taking a statin were never offered the therapy

Literature - Apr. 11, 2019 - Bradley CK et al. - J Am Heart Assoc. 2019

The PALM registry reveals that 27% of adults who were eligible for statin therapy, did not use it. In almost 60%, this was because they were never offered a statin. Others discontinued, or declined use

Safety of cholesterol biosynthesis inhibitor in high CV risk patients

Literature - Apr. 9, 2019 - Ray KK et al. - NEJM 2019

Safety of bempedoic acid was studied over a 1-year period in the CLEAR Harmony trial, which enrolled high CV risk patients.

Inhibition of enzyme upstream of statin target also lowers LDL-c levels and CV event risk

Literature - Apr. 8, 2019 - Ference BA et al - N Engl J Med 2019

Mendelian randomization study provides genetic validation for ATP citrate lyase as target (of bempedoic acid) in LDL-c lowering to reduce CV risk, to a similar extent as inhibiting HMGCR with a statin.

Higher consumption of dietary cholesterol or eggs linked to increased risk of incident CVD and mortality

Literature - Apr. 4, 2019 - Zhong VW et al. - JAMA 2019
Among US adults, higher consumption of dietary cholesterol or eggs was significantly associated with higher risk of incident CVD and all-cause mortality in a dose-response manner.

Among US adults, higher consumption of dietary cholesterol or eggs was significantly associated with higher risk of incident CVD and all-cause mortality in a dose-response manner.

Challenges for screening and treatment of FH patients in clinical cardiology

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Causal association of LCL-c with ischemic stroke and intracerebral hemorrhage

Literature - Mar. 29, 2019 - Sun L et al. - Nature Medicine 2019
Observational and genetic analyses found a causal positive association of LDL-c with ischemic stroke and a causal negative association with ICH in a Chinese population. Using randomized trial data, a net benefit for the prevention of overall stroke with lowering LDL-c was shown.

Observational and genetic analyses found a causal positive association of LDL-c with ischemic stroke and a causal negative association with ICH in a Chinese population. Using randomized trial data, a net benefit for the prevention of overall stroke with lowering LDL-c was shown.

PCSK9 inhibition: Science, outcomes & guidance

CME accredited E-Learning

Online-CME - This course consists of an introduction and 3 lectures
This course consists of an introduction and 3 lectures

CME accredited course focussed on PCSK9 inhibitors as novel strategy to reduce LDL-C. Member registration (free) is needed to enroll in this course

Large absolute benefit with PCSK9 inhibitor in ACS patients with polyvascular disease

Literature - Mar. 27, 2019 - Jukema JW, et al. - JACC 2019

A prespecified analysis of the ODYSSEY OUTCOMES trial showed a higher incidence of MACE and death in ACS patients with polyvascular disease and alirocumab treatment resulted in a large absolute benefit in these patients.

Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

3' education - Mar. 19, 2019 - Anne Carol Goldberg, MD
The results of the CLEAR WIsdom trial are summarized by prof Goldberg, with lowering of LDL-c in response to bempedoic acid vs placebo as most important finding.

ACC 2019 The results of the CLEAR WIsdom trial are summarized by prof Goldberg, with lowering of LDL-c in response to bempedoic acid vs placebo as most important finding.

Cholesterol synthesis inhibitor reduces LDL-c in high CV risk patients

News - Mar. 19, 2019

ACC 2019 Results of the CLEAR Wisdom trial showed that bempedoic acid lowered LDL-c in high CV risk patients with elevated LDL-c levels who are on maximally tolerated statin and/or other lipid-modifying therapies.

How are the guidelines for progressive CAD guiding us in clinical practice?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser
Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.

Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.

LDL-c & PCSK9i in Clinical Cardiology
LDL-c & PCSK9i in Clinical Cardiology
LDL-c & PCSK9i in Clinical Cardiology
LDL-c & PCSK9i in Clinical Cardiology
LDL-c & PCSK9i in Clinical Cardiology